David Chism, Medical Oncologist at Tennessee Oncology, shared a post on LinkedIn:
“Zip-Speed Innovation, ZIP-Code Access: The Immunotherapy Paradox
Since 2017, CAR-T and bispecific therapies have advanced at zip speed. What began with two CAR-T approvals has expanded into a powerful immunotherapy platform.
Access hasn’t kept up.
FACT-accredited immune effector cell programs increased from ~24 centers in 2018 to ~178 by 2025—real progress, but still geographically limited and workforce-dependent.
Immunotherapy doesn’t fail because of science.
It fails when access is determined by ZIP code.
Access gaps don’t just limit immunotherapy—they create space for misinformation.
Today’s innovation needs tomorrow’s delivery.”
More posts featuring David Chism.